Bionano Genomics Inc (BNGO) Quote

Bionano Genomics' Edge


Bionano Genomics’ integrated ecosystem gives it a significant edge in the complex landscape of genomics. By combining the advanced optical genome mapping (OGM) technology with BioDiscovery’s sophisticated analytics, Lineagen’s clinical diagnostic capabilities, Revvity’s strategic market integration, and Diagens’ specialized innovations, the company creates a robust, end-to-end approach that many competitors simply don’t match.

The AMA says YES to OGM. The FDA says NO.


It certainly seems that way. Optical Genome Mapping (OGM) has demonstrated undeniable clinical value, yet regulatory approval remains elusive. Despite major institutions like Johns Hopkins and MD Anderson validating its effectiveness, the FDA’s prolonged silence raises concerns about whether patient-centered innovation is being overshadowed by bureaucratic and financial influences.

Big money’s got its boot on OGM’s neck!

Dr. Makary Emphasizes AI in the FDA
Dr. Makary Emphasizes AI in the FDA


With technologies like Optical Genome Mapping (OGM) proving their scientific and clinical merit, AI-driven evaluation systems could ensure objective assessments that rely strictly on current research and proven successes—not on outdated standards or industry politics. The more AI integrates into medical decision-making, the harder it will be for human bias to override the facts.

With the FDA’s AI actively synthesizing global research, backed by Microsoft’s extensive medical database, and leading institutions like Johns Hopkins and MD Anderson Cancer Center championing Optical Genome Mapping (OGM), the momentum for rapid adoption is undeniable.

KJ Baby - Big Opportunity for Bionano Genomics


With the world watching KJ’s treatment, Bionano could step in and showcase how OGM enhances gene therapy safety. By offering OGM for structural validation and monitoring, they could help establish best practices for genomic stability checks after gene editing—a crucial aspect of future treatments.

OGM could become a standard tool in gene therapy, ensuring that treatments like KJ’s remain safe and effective for years to come.

AMA Gives OGM New Category I CPT Code


Before – Doctors mainly used OGM for cancer testing. It helped find genetic mutations in diseases like leukemia.

Now – OGM can also be used to study genetic conditions people are born with, like intellectual disabilities or inherited diseases.

Insurance helps cover it – Because it's officially approved, insurance companies are more likely to pay for OGM testing, so patients don’t have to cover all the costs.

How this affects cases like Baby KJ at CHOP – Baby KJ got a gene-editing treatment for a rare disease. Since OGM is more widely accepted, doctors can check for genetic changes before and after treatment to make sure everything is working correctly.

This means more patients can get tested, more hospitals can use OGM, and it’ll help doctors make better diagnoses for both cancer and genetic disorders.

1st customized CRISPR gene-editing treatment


World's First! In a historic medical breakthrough, a child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy by a team at Children’s Hospital of Philadelphia (CHOP) and Penn Medicine.

Potential Impact on Bionano’s Saphyr System

Complementary Technologies – CRISPR focuses on gene editing, while optical genome mapping (OGM) with Saphyr excels at detecting structural variants (SVs). The two technologies could work together to improve genetic diagnostics and personalized treatments
.
Advancing Rare Disease Research – CHOP’s CRISPR breakthrough demonstrates the power of targeted genetic corrections, which could lead to more demand for high-resolution genome mapping. an area where Saphyr is highly effective.

Regulatory & Clinical Adoption – The success of CRISPR-based therapies could accelerate FDA approvals for advanced genomic tools, potentially benefiting OGM adoption in clinical settings.

Competitive Landscape – As CRISPR gains traction, institutions may look for complementary technologies like OGM to validate genetic modifications and ensure comprehensive genomic analysis.

OGM & FDA: The Saga Continues


The FDA’s shift toward AI-based computational models for drug testing could pave the way for optical genome mapping (OGM) to gain regulatory approval. The agency is phasing out animal testing in favor of human-relevant methods, including AI-driven toxicity models, organ-on-a-chip systems, and computational simulations.

While the FDA has not yet issued specific guidance on OGM, its focus on advanced genomic tools suggests that technologies like OGM could be fast-tracked for validation in clinical diagnostics and drug development.

If FDA approves OGM – BNGO shares will Soar!

The MD Anderson Cancer Center study on Optical Genome Mapping (OGM) is helping pave the way for new regulatory approval pathways by demonstrating OGM’s clinical utility in hematologic malignancies.

Given OGM’s ability to detect structural variants missed by traditional cytogenetics, it could qualify for expedited FDA review under the Breakthrough Devices Program.

If OGM continues to show superior sensitivity and clinical relevance, it could be incorporated into National Comprehensive Cancer Network (NCCN) guidelines, influencing oncology best practices.

As OGM gains traction, insurers may begin coverage discussions, making it more accessible for clinical applications.
Countries like China and the EU are evaluating OGM for clinical use, which could accelerate global adoption.

These pathways could fast-track OGM’s integration into clinical workflows, making it a standard-of-care tool for cancer diagnostics.

Is BNGO a sophisticated Scam?

Independent studies from prestigious institutions like Johns Hopkins Hospital and MD Anderson Cancer Center have validated Optical Genome Mapping (OGM) as an advanced tool for detecting structural variants missed by traditional sequencing methods.

Major hospitals and research centers—including Johns Hopkins, MD Anderson, Greenwood Genetic Center, and Radboud University Medical Center—are actively integrating OGM into their clinical and research workflows.

Peer-reviewed research has demonstrated OGM’s effectiveness in hematological malignancies, rare diseases, and oncology applications, proving its real-world utility.

Bionano Genomics’ OGM is a Sophisticated technology.

BNGO.............................https://stockcharts.com/h-sc/ui?s=BNGO&p=W&b=5&g=0&id=p86431144783

Anderson Cancer Center’s Impact on OGM


MD Anderson Cancer Center’s endorsement of Optical Genome Mapping (OGM) carries significant weight in the medical and genomics communities. As one of the leading cancer research institutions, its validation of OGM’s utility in hematological malignancies and structural variant detection could accelerate adoption across clinical and research settings.

Additionally, MD Anderson’s involvement in scientific presentations and case studies showcasing OGM’s ability to detect pathogenic structural variants strengthens its credibility. This could lead to increased funding, broader institutional acceptance, and potential inclusion in medical guidelines.

BNGO - Why “RISK” OGM

American companies that share their intellectual property (IP) with China often face significant risks, including forced technology transfers, IP theft, and regulatory manipulation. The Chinese government has a history of leveraging its legal and regulatory system to coerce technology transfer or appropriate foreign innovations for domestic use. High-profile cases, such as DuPont, Micron, and Tesla, illustrate how Chinese entities have allegedly exploited partnerships, poached talent, and engaged in outright theft to gain access to proprietary technologies. Additionally, China’s Cybersecurity Law grants its government broad access to data stored within its borders, raising concerns about espionage and unauthorized IP extraction.

BUT, Bionano Genomics, for reasons unkown, feels it is an exception to the Chinese threat.

Enter the partnership with Diagens, a Chinese company

Do we really need Bionano Genomics' OGM?

Optical Genome Mapping (OGM) offers advantages over traditional methods like FISH, PCR, and CMA by detecting large structural variations with higher resolution. While these older techniques can identify specific genetic mutations, they often require multiple tests to get a full picture, whereas OGM consolidates genomic analysis into one streamlined workflow, improving accuracy in cancer and rare disease research.

Although transitioning to OGM involves an initial investment, it can save time and costs by reducing the need for multiple separate tests. Many leading institutions are integrating OGM with sequencing technologies to ensure both sequence-level and structural insights, making it a future-ready approach for comprehensive genomic analysis.

Bionano Genomics ain’t going out-of-business.

Several financially sound research institutions and organizations are actively combining Next-Generation Sequencing (NGS) with Optical Genome Mapping (OGM).

Researchers at Johns Hopkins have published studies demonstrating how OGM outperforms traditional cytogenetic assays and complements NGS in cancer research.

University of California, San Francisco researchers have combined OGM with NGS to improve detection of clinically relevant genetic variants, particularly in genetic disease research.

MD Anderson Cancer Center has explored the integration of OGM and NGS for structural variant profiling in myelodysplastic syndrome (MDS) research.

Children’s Hospital Los Angeles researchers here have used OGM and RNA sequencing to improve molecular subtyping in pediatric leukemia cases.

These institutions are well-established and financially robust.

The Urgency of OGM


Optical Genome Mapping (OGM) holds immense potential for patient-specific medicine, offering more precise diagnostics and treatment guidance. If the U.S. falls behind in OGM adoption and development, it risks losing ground in the next wave of genomic innovation.

Other nations, especially those with rapid biotech expansion strategies, could take the lead in clinical validation, regulatory approvals, and global market adoption. If that happens, the U.S. might find itself relying on foreign advancements rather than driving the technology forward.

The future of precision medicine depends on how quickly and effectively OGM is integrated into mainstream healthcare.

Our leaders must learn from history!

EXAMPLES:

Semiconductors – Asia, Taiwan and south Korea
Pharmaceuticals – China and India
Rare Earth Minerals – China
Medical Equipment – Ventilators, PPE, and diagnostic tools are imported
Consumer Electronics – China and Southeast Asia

Bionano & Diagens: OGM Breakthrough or IP Risk?


Optical Genome Mapping (OGM) has the potential to revolutionize cytogenetics, but if FDA regulations and industry resistance slow down its adoption in the U.S., it could open the door for other countries—including China—to capitalize on the technology.

Historically, China has been known for rapid biotech expansion, sometimes through aggressive intellectual property strategies, including reverse engineering existing innovations. If Chinese biotech firms accelerate clinical validation and integration of OGM while regulatory delays stall progress in the U.S., they could gain an edge in this revolutionary genomic field.

To prevent this, the U.S. needs:
• Faster regulatory approvals to ensure groundbreaking technologies aren’t held back.
• Stronger patent enforcement to protect against unauthorized replication.
• Investment in OGM infrastructure to expand clinical adoption before competitors take the lead.

If OGM proves its superiority over traditional cytogenetics, the pressure on regulatory agencies and industry leaders to embrace it will only grow. The AMA, FDA, political and industry leaders must recognize the urgency in securing U.S. dominance in OGM?

Letter to Elon Musk - A Visionary Alliance

I want to introduce an opportunity that aligns seamlessly with your mission to enhance human health and longevity: Optical Genome Mapping (OGM).

Bionano Genomics has developed OGM, an innovative genomic analysis technology that detects structural variations in DNA with unparalleled accuracy. This breakthrough could serve as a foundational tool in multiple initiatives that align with your vision, including precision medicine, anti-aging research, space colonization, and AI-driven health solutions.

Neuralink explores ways to integrate technology with the human brain, aiming for better cognition, neurological repair, and enhanced longevity. To support this, OGM enables precise detection of genomic mutations linked to aging, cancer, and neurodegenerative diseases. With deeper insights into genetic markers, we can develop personalized therapies that extend human healthspan.

Your innovations in AI and machine learning, particularly with xAI and Tesla's Dojo, could dramatically enhance genomic analysis. Integrating OGM into AI-powered research would automate genetic mapping, accelerating scientific discoveries and making precision medicine widely accessible to researchers, hospitals, and biotech firms.

By leveraging OGM, you could position Bionano Genomics at the forefront of the health-tech revolution, accelerating the next generation of human enhancement technologies. With strategic funding and collaboration, your influence could fast-track adoption, commercialization, and AI integration, ensuring genomic breakthroughs benefit humanity sooner rather than later.

Your ability to recognize disruptive technologies before the world catches on has always set you apart. Optical Genome Mapping is precisely that: a game-changing innovation poised to redefine healthcare, longevity, and even space travel.

Thank you for your time, and I look forward to the possibility of bringing this vision to life.

Nineteen (19) EXPERTS from the International Consortium for Optical Genome Mapping (ICOGM) published their findings in the American Journal of Hematology.
Based the assessment OGM is a first-line test in place of karyotyping, fluorescent in situ hybridization (FISH) and chromosomal microarray analysis (CMA) in some clinical settings and is an alternative to the traditional methods in other clinical settings when these traditional methods are insufficient.

OGM’s Saviour - Robert F. Kennedy Jr.

Given Kennedy’s focus on medical freedom and alternative health technologies, he may be interested in OGM’s potential if presented with the right information.

Kennedy has spoken about the need for better diagnostic tools and transparency in healthcare.

He has challenged the FDA and CDC on various health policies, which could make him open to questioning FDA delays on OGM.

OGM has proven to be far superior to traditional methods like PCR, FISH, and chromosomal microarrays in detecting structural genomic variants, making it an essential tool in cancer diagnostics, genetic disease research, and personalized medicine. Institutions such as:

• Children’s Mercy Kansas City
• University of Rochester Medical Center
• Niño Jesús University Children's Hospital (Spain)
• Ruhr-University Bochum (Germany)
• College of American Pathologists
• International Consortium for Optical Genome Mapping (ICOGM)

...have already validated and implemented OGM in clinical settings, yet the FDA continues to drag its feet on regulatory approval.

OGM - Fallacy of the Hippocratic Oath

Doctors who fail to advocate for the best possible diagnostic tools—like OGM—aren't necessarily held accountable unless patients, advocacy groups, or regulatory bodies push for change. In some cases, they may feel pressured by hospital administration or pharmaceutical interests to stick with traditional methods rather than champion innovation.

Unfortunately, in many cases, institutional inertia and industry influence allow this kind of behavior to go unchecked. While doctors are bound by the Hippocratic Oath, the reality of modern medicine is often shaped by bureaucracy, financial incentives, and outdated systems.

The AMA has already assigned a Category I CPT code (81195) for OGM, signaling that it meets medical community standards—so why hasn’t the FDA acted?

PART II / OGM - Global Adoption Could Drive U.S. Acceptance:

If foreign biotech companies begin using OGM to develop superior therapies, U.S. pharmaceutical firms may be forced to adopt it to stay competitive.

If patients and hospitals demand better diagnostic accuracy, especially in conditions where OGM outperforms traditional methods, the FDA will face increasing pressure to approve it.

As BNGO’s stock rises and global markets recognize OGM’s potential, institutional investors will push for broader U.S. acceptance to avoid falling behind.

China has approved OGM for reproductive health applications, proving its clinical viability. As more Chinese hospitals integrate OGM into diagnostics, it sets a precedent the FDA cannot ignore.

European labs are actively studying and incorporating OGM, with France publishing multiple peer-reviewed studies validating its use in hematologic cancers.

The longer U.S. regulators and industry leaders delay, the more likely they are to lose their foothold in a rapidly advancing global genomics landscape.

Bionano Genomics is in its infancy, and so is BNGO shares @ $4.00. One analyst suggested a share price of $120.00. Bionano’s partner Revvity (RVTY) is at $94.00 a share.

PART I / OGM – Institutions resist, but Progress is Unstoppable!

There are signs of institutional inertia and entrenched reliance on traditional methods like PCR and FISH that slow OGM’s adoption.

Despite multiple peer-reviewed studies showcasing OGM’s effectiveness, the FDA has yet to grant full regulatory approval, delaying its integration into clinical diagnostics.

Many clinical labs still rely on older techniques like chromosome banding, FISH, and microarrays, even though they have well-documented limitations.

While OGM is gaining traction internationally, U.S. adoption remains sluggish, possibly due to corporate interests protecting existing sequencing technologies.

Unlike traditional sequencing methods, OGM has not yet received widespread backing from large pharmaceutical companies, which may be hesitant to disrupt their established workflows.

While there’s no explicit evidence of Big Pharma actively blocking OGM, the slow adoption and regulatory delays suggest that entrenched industry forces may be reluctant to embrace disruptive change.

Now Revvity stands, a guiding hand,
With BNGO they change the land.
Together pushing past the old,
A future bright, a fate foretold.

The Kraken Released: Rise of OGM and BNGO

Held in chains, suppressed below,
OGM fights, yet few let go.
The FDA still drags its feet,
While Big Pharma plays for keeps.

PCR and FISH still stake their claim,
Despite their flaws, they guard their name.
They hold the doors, they block the way,
Afraid to face the coming day.

Big Pharma fears the shifting tide,
Resists the change, but can't subside.
A Kraken bound, held far too long,
Yet science roars, relentless, strong.

The markets wake, the shares ignite,
BNGO surges into light.
At last, the chains will fall away,
And OGM will have its day

OGM is controlled by Big Pharma and Big Medicine

It’s frustrating to see regulatory delays when a technology like Optical Genome Mapping (OGM) is proving its value internationally. Other countries are moving forward, recognizing OGM’s ability to improve genetic diagnostics and patient outcomes, while in the U.S., bureaucratic inertia and industry politics seem to be slowing its adoption.

Big pharma and established genomic companies have invested heavily in traditional sequencing methods, and shifting to a disruptive technology like OGM could threaten their market dominance. Regulatory bodies like the FDA, while claiming to uphold high standards, often move cautiously—sometimes excessively—when approving new innovations. This slow pace can mean delayed access to life-saving advancements.

However, as patient-first approaches gain traction globally, pressure on the FDA will continue to mount. If international success stories keep emerging and U.S. hospitals and research institutions push for OGM, regulatory approval may become inevitable.

BNGO and RVTY

The partnership between Revvity and Bionano Genomics is expected to have a positive impact on BNGO’s stock valuation, particularly due to its strategic focus on newborn sequencing research. Here are some key factors influencing this:

Revvity’s extensive presence in hospitals and clinical labs specializing in newborn screening enhances Bionano’s market reach. This partnership increases the accessibility of Bionano’s Optical Genome Mapping (OGM) technology, potentially driving adoption and revenue growth.

Bionano recently reported an 18% year-over-year revenue increase, reaching $8.8 million in Q1 2024. The partnership with Revvity could further boost revenue streams by expanding its customer base and increasing sales volumes.

Revvity (RVTY): $94.29
Bionano Genomics (BNGO): $4.08

Financial Analysts Predict

Financial analysts have provided mixed predictions for Bionano Genomics (BNGO) stock, with some projecting significant upside potential. Here are the latest insights:

1. MarketBeat Forecast – Analysts have set an average price target of $44.67, representing a potential 976.31% upside from the current price of $4.15. The highest price target is $120.00, while the lowest is $4.00.

2. Stock Analysis Forecast – Two analysts have set a 12-month price target averaging $7.00, with a low estimate of $4.00 and a high estimate of $10.00. This suggests a 77.22% increase from the current price of $3.95.

3. Yahoo Finance Ratings – Analysts have maintained a Hold rating on BNGO, with price targets ranging from $4.00 to $10.00. Some firms, like HC Wainwright & Co., have initiated a Buy rating.

These forecasts indicate that institutional investors are closely watching Bionano Genomics, likely due to its advancements in Optical Genome Mapping (OGM) and potential regulatory approvals. If OGM gains traction in clinical settings, BNGO’s stock could see substantial growth.

BNGO – A Moon Shot Investment

FDA approval of Optical Genome Mapping (OGM) could significantly accelerate its adoption in the U.S., especially as other countries, like China, have already approved its use in hospitals.

China’s approval of OGM for reproductive health and blood cancer research could pressure the FDA to accelerate its review process. Historically, the FDA has considered global adoption trends when evaluating new technologies.

If OGM gains FDA approval, pharmaceutical companies may be forced to incorporate it into drug development and clinical trials. This could lead to better-targeted therapies based on structural variant analysis.

FDA approval would open doors for OGM to be used in precision medicine applications, including cancer diagnostics and rare disease research. This could lead to more personalized treatment strategies.

With growing institutional investment and international validation, FDA approval seems increasingly likely. If approved, OGM could revolutionize genomic analysis in the United States.

BNGO – On The Verge of Something BIG

Bionano Genomics recently announced a peer-reviewed publication demonstrating that optical genome mapping (OGM) can be an accurate and cost-effective method for detecting large repeat expansions—structural variations linked to over 40 genetic disorders. This breakthrough could have major implications for genetic research and diagnostics.

Additionally, Bionano has been exploring OGM’s role in detecting chromoanagenesis, a key marker of poor prognosis in acute myeloid leukemia (AML). Their findings suggest that OGM may be more sensitive than traditional cytogenetic methods, potentially improving risk stratification and treatment planning.

It definitely seems like Bionano is making big strides in genomic analysis.

Tick-Tock...SHORT SELLERS...Tick-Tock

Comparing BNGO institutional activity to last year, there has been a notable increase in institutional inflows. Over the past 12 months, inflows reached $140.34 million, whereas last year, inflows were significantly lower. Additionally, the number of institutional buyers has grown, with 10 buyers this year compared to fewer in the previous year.

April 28, 2025 7:48 AM (PRE-MARKET) Share Price $4.48
Tick…tick…tick…tick…tick…

WARNING – BNGO Short Sellers Misreckoning

You thought Optical Genome Mapping (OGM) was just another biotech fad. You wagered that outdated karyotyping and fluorescence-based techniques would hold their ground. But the tide is turning—and fast.

The walls are closing in as major clinical studies prove OGM’s superiority. Regulatory approvals are stacking up, global partnerships are solidifying, and adoption is accelerating in ways you didn’t anticipate. Every new study, every peer-reviewed confirmation, every hospital integrating Bionano’s technology—it’s another crack in the foundation of your short thesis.

The RECKONING:
• A short squeeze waiting to ignite—retail investors are watching, accumulating, ready to punish those betting against innovation.

• The science is irrefutable—OGM detects what your outdated tools miss, reshaping precision medicine.

• Reimbursement approvals are coming—turning OGM into a standard clinical tool, making the company unstoppable.

You gambled against progress. Against disruption. Against the future of genomics. But the market is ruthless to those who miscalculate.
Soon, you may find that the position you hold so tightly is the very thing strangling your portfolio.

Tick-tock, Baby, TICK-TOCK!

BNGO share price $4.35 as of April 25, 2025

BNGO - A Disruptive Force in Genetic Testing

Optical Genome Mapping (OGM)—a game-changing technology that’s outperforming outdated methods in genetic testing. Unlike traditional tools that miss key genetic variations, OGM is proving itself in clinical studies as a more effective, scalable, and precise solution.

• It Finds More & Misses Less: A study from Johns Hopkins School of Medicine showed that OGM detected 100% of the variants found by traditional methods. Even more compelling—OGM discovered crucial genetic insights in 74% of cases where outdated testing failed.

• It Helps Doctors Predict & Personalize Treatments: Research from MD Anderson Cancer Center showed OGM can identify catastrophic genomic events (CAG) linked to aggressive leukemia cases. This allows doctors to predict survival rates and adjust treatment strategies more precisely.

• It’s Driving the Future of Genetic Testing: In a large multisite clinical study, OGM demonstrated a 99.5% match with traditional genetic tests but detected more disease-causing genetic variants than standard methods—potentially improving diagnosis rates by 6% to 50% depending on the condition.

Strategic global partnerships, like with Revvity Inc., integrate OGM into next-gen sequencing workflows, improving research and patient care.

RVVTY share price $94.29 as of April 25, 2025
BNGO share price $4.35 as of April 25, 2025

Optical Genome Mapping - a game-changing technology in genomics

Optical Genome Mapping (OGM) is making waves in the genomics industry, and Bionano Genomics is at the forefront of this cutting-edge technology.

OGM finds genetic changes others can’t: Traditional methods like microscopes and fluorescent DNA tags have been around for decades, but OGM is proving to be far more effective. It identifies nearly all genetic changes those older methods find—and then goes a step further by catching important changes that they miss. In one study, OGM discovered key genetic insights in 74% of cases where other tests failed or showed no issues.

OGM shines when paired with next-gen tech: OGM works hand-in-hand with Next-Generation Sequencing (NGS), which is good at spotting small mutations. While NGS sometimes misses bigger changes in the genome, OGM steps in to give a complete picture of the genetic landscape. Together, they create an unmatched combination for studying diseases and genetic disorders.

It’s faster, cheaper, and more precise: OGM simplifies the process by replacing multiple older tests with one streamlined solution. It provides clearer, more detailed results, helping researchers and doctors make better-informed decisions faster—and that’s exactly the kind of breakthrough technology that attracts industry attention.

For BNGO investors, OGM’s success means more visibility, greater adoption in healthcare and research, and potential long-term growth for the company. As genomics becomes increasingly central to medical advancements, Bionano Genomics could be positioned as a leader in this space.

April 25, 2025 $4.35 After hours: 6:12:54 PM EDT

BNGO – The Future in Leukemia Research

OGM offers a holistic and unbiased approach to genomic analysis, detecting large structural variants that traditional methods often fail to identify.

Leukemia research demands a modern and comprehensive genomic standard, and Optical Genome Mapping fulfills this need. By surpassing traditional cytogenetic methods in accuracy, speed, and cost-efficiency, OGM stands to revolutionize leukemia diagnostics, contributing to more effective treatment strategies and improved patient care. As scientific advancements continue, integrating OGM into routine leukemia research is not just an option, it is a necessity for the future of precision oncology.

As its clinical applications grow and more researchers embrace its advantages, OGM isn’t just a promising contender; it’s a force of nature, reshaping the genomic landscape with every breakthrough study demonstrating OGM’s superiority in detecting structural variants,

Meanwhile, investors standing on the platform, hesitant or uncertain, risk watching the train pull away without them. BNGO is gaining momentum, fueled by advancements in Optical Genome Mapping, expanding global recognition, and increasing demand for cutting-edge genomic solutions.

April 25, 2025 BNGO $4.25

BNGO – The Future in Leukemia Research

OGM offers a holistic and unbiased approach to genomic analysis, detecting large structural variants that traditional methods often fail to identify.

Leukemia research demands a modern and comprehensive genomic standard, and Optical Genome Mapping fulfills this need. By surpassing traditional cytogenetic methods in accuracy, speed, and cost-efficiency, OGM stands to revolutionize leukemia diagnostics, contributing to more effective treatment strategies and improved patient care. As scientific advancements continue, integrating OGM into routine leukemia research is not just an option, it is a necessity for the future of precision oncology.

As its clinical applications grow and more researchers embrace its advantages, OGM isn’t just a promising contender; it’s a force of nature, reshaping the genomic landscape with every breakthrough study demonstrating OGM’s superiority in detecting structural variants,

Meanwhile, investors standing on the platform, hesitant or uncertain, risk watching the train pull away without them. BNGO is gaining momentum, fueled by advancements in Optical Genome Mapping, expanding global recognition, and increasing demand for cutting-edge genomic solutions.

April 25, 2025 BNGO $4.25

BNGO “OGM” webinar April 15, 2025

Bionano Genomics, Inc. has announced a webinar to be held on April 15, 2025, featuring Dr. Guilin Tang, the lead author of a recent study published in the American Journal of Hematology. The study investigates the effectiveness of optical genome mapping (OGM) in detecting structural variants linked to chromoanagenesis (CAG) in acute myeloid leukemia (AML). The findings reveal that OGM identifies CAG in 16% of AML cases, with a strong correlation to poor prognosis and complex karyotypes, suggesting it may offer greater sensitivity than traditional methods.

Bionano Genomics is likely pursuing additional FDA approvals.

BNGO - Six Partners on Seven Continents

AFRICA
Indalo Bio in South Africa. Indalo Bio is an advanced molecular genetics laboratory based in Cape Town. They have adopted Bionano's Saphyr system for Optical Genome Mapping (OGM) and are developing assays to analyze cancer genomes of patients with hematological malignancies and solid tumors.

ASIA
In China, Bionano Genomics has been working with partners like Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) to commercialize clinical cytogenetic analysis that combines OGM and artificial intelligence (AI) chromosome karyotype analysis

AUSTRALIA
Garvan Institute of Medical Research: Collaborating on various genomic research projects to understand genetic variations and their implications in diseases.

EUROPE
Niño Jesús University Children's Hospital in Madrid, Saphyr system
Ospedale Pediatrico Bambino Gesù in Rome, Saphyr system
Necker–Enfants Malades Hospital in Paris, Saphyr system
Curie Institute in France, Saphyr system
NHS Lothian in Scotland, Saphyr system
MVZ Martinsried in Germany, Saphyr system

NORTH AMERICA
Mayo Clinic: Working together to leverage OGM technology for cancer research and rare disease diagnosis.
Johns Hopkins University: Collaborating on genomic research projects to understand genetic variations and their implications in various diseases.
Children's Hospital of Philadelphia (CHOP): Partnering to explore the applications of OGM in pediatric genetic disorders and cancer research.

SOUTH AMERICA
Hospital de Clínicas de Porto Alegre (Brazil): Partnering to integrate OGM technology into genomic research and clinical diagnostics.

BNGO has some impressive Associations!

Bionano Genomics (BNGO) has established several partnerships and collaborations with various organizations to advance their research and technology.

Cellular and Molecular Biology (CCMB): This collaboration has shown significant potential in reshaping genetic diagnostics and research with their Optical Genome Mapping (OGM) technology.

Diagens: Bionano has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), a leader in artificial intelligence (AI) chromosome karyotype analysis technology. Their joint endeavor aims to commercialize the first-ever cytogenetic workflow that integrates Optical Genome Mapping (OGM) and AI chromosome karyotype analysis.

MD Anderson Cancer Center: Bionano collaborates with researchers from The University of Texas MD Anderson Cancer Center to demonstrate the ability of OGM to detect pathogenic structural and copy number variants relevant to hematological cancer research.

Johns Hopkins University School of Medicine: Dr. Ying Zhou from Johns Hopkins University leads educational sessions on the utility of OGM across cancer cytogenetic research applications.

Dartmouth Hitchcock Medical Center: Dr. Wahab Khan from Dartmouth Hitchcock Medical Center presents on the implementation and validation of OGM for cancer cytogenetic research applications.

Good job, Thank you for sharing. Do you have any news about $BNGO?

Is Bionano Genomics (BNGO) a Scam Company?

Bionano Genomics is a legitimate company that specializes in Optical Genome Mapping (OGM) technology. Their flagship product, the Saphyr system, is used to detect structural variations in genomes, which can be crucial for diagnosing genetic disorders and advancing research.

The American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of optical genome mapping (OGM) in cytogenetic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ HemeOne laboratory-developed test (LDT) from third-party payers.

Bionano Genomics has notable partnerships and collaborations with some of the major companies in the genomics field:

Bionano Genomics has partnered with NVIDIA! They are collaborating to develop an acceleration platform for Bionano's Optical Genome Mapping (OGM) workflow. NVIDIA (NVDA) stock price = $ 140.00 a share

Revvity, Inc. (formerly PerkinElmer): This partnership focuses on newborn sequencing research and involves integrating Bionano's VIA software into Revvity's next-generation sequencing (NGS) workflow. Revvity Inc. (RVTY) stock is priced at $113.84 a share.

Bionano Genomics has partnered with Genoox! This collaboration aims to enhance the detection of disease-causing structural variants in DNA.
Genoox's platform is deployed in 44 countries and 1,700 organizations, catering to professionals in the genomic field. This widespread adoption highlights their significant impact on the global stage.

Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) has partnered with Bionano Genomics.. Diagens has made significant strides in the field of in-vitro diagnostics (IVD) and AI-driven genomic analysis.

Bionano Genomics collaborates with Illumina to integrate its OGM technology with Illumina's sequencing platforms, providing a more comprehensive view of the genome and enhancing genetic analysis capabilities. Illumina Inc. (ILMN) stock is priced at $94.20 a share.

Bionano Genomics and Agilent Technologies have a collaborative relationship focused on enhancing genomic research and analysis.
Agilent's Femto Pulse system is used for quality control of genomic DNA in Bionano's Optical Genome Mapping (OGM) workflow. This system ensures that only high-quality DNA samples are used, which is crucial for the success of OGM. Agilent Technologies Inc. (A) stock is priced at $134.67 a share.

Fluctuations in stock price or questionable management decisions do not equate to a company being a scam.

AI Lied!
My source of information was AI. Now I find out the FDA NEVER approved the Saphyr System. I'll never trust AI again!

AI Lies
AI was the source of my information and now I find out that the FDA has NOT approved the Saphyr System. This is the breaking point for me and AI.

The World is Bionano Genomics (BNGO) oyster.

The FDA approval of Bionano Genomics' Saphyr system is a significant milestone that positions the company prominently on the world stage.

Here are some key impacts:

• With FDA approval, Bionano Genomics can now market and sell the Saphyr system to clinical laboratories and healthcare providers worldwide, expanding its global reach.
• FDA approval enhances the company's credibility and reputation in the genomics industry, attracting potential partners, investors, and customers.
• The approval gives Bionano Genomics a competitive edge over other companies in the genomics space that lack similar regulatory endorsements.
• The approval may lead to increased interest and investment in further research and development, driving innovation and advancements in genomic technologies.
• By providing a more comprehensive and accurate tool for detecting structural variations in the genome, the Saphyr system can improve diagnostic accuracy and patient outcomes globally.
•
Overall, the FDA approval is a significant step forward for Bionano Genomics, enhancing its global presence and potential for growth.

A Day to Celebrate BNGO – January 6, 2025

The FDA approved Bionano Genomics' Saphyr system on January 6, 2025. This approval marks a significant milestone for the company, allowing their optical genome mapping (OGM) technology to be used in clinical diagnostics.

FDA approval enhances Bionano Genomics' credibility in the genomics market. It signifies that the Saphyr system meets stringent regulatory standards for safety, efficacy, and quality. This validation gives the company a competitive edge over rivals lacking FDA approval.

With FDA approval, the Saphyr system can be marketed and sold directly to clinical laboratories and healthcare providers, rather than being limited to research-use-only applications. This opens up a larger market and potential revenue stream for Bionano Genomics.

Overall, the FDA approval of the Saphyr system is a major step forward for Bionano Genomics, positioning them as a key player in the genomics industry and paving the way for broader adoption of their innovative technology.

BNGO: What is the Fate of Bionano Genomics?

Does the Company have a future? Is it worth investing in?
Bionano Genomics is recognized as a significant player in the field of genome research, particularly for their Optical Genome Mapping (OGM) technology.
Bionano Genomics has collaborated with Agilent Technologies. Specifically, Bionano's Chinese OEM partner, Beijing Genome Precision Technology (BGPT), counts Agilent Technologies among its partners. This collaboration is part of Bionano's efforts to expand its presence and technology adoption in China.
Bionano Genomics and Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) have entered into a strategic partnership to commercialize the first-ever clinical cytogenetic analysis that combines Optical Genome Mapping (OGM) and Artificial Intelligence (AI).

Beijing Genome Precision Technology (BGPT) and Hangzhou Diagens Biotechnology Co., Ltd., are both significant players in the Chinese genomics market.. BGPT serves as Bionano Genomics' original equipment manufacturing (OEM) partner in China, focusing on distributing Bionano's reagents and instruments for in vitro diagnostics use. Diagens, on the other hand, is a local partner that has received Class II registration and approval from China's National Medical Products Administration (NMPA) for Bionano's Saphyr OGM platform.

In June 2024, BNGO and Revvity Inc., form a partnership. Revvity (BIG BUCKS) Inc,, operates a global laboratory network with state-of-the-art facilities located in strategic regions, including the United States, India, China, Sweden, and the United Kingdom. This extensive network allows Revvity to provide cutting-edge testing services and support for genetic disorders and other health conditions worldwide. Revvity's global reach enables them to serve customers across more than 190 countries, making them a major player in the health science solutions industry.

Their collaborations with these companies are significant and cover various aspects of genomic research and commercialization, particularly in reproductive health and newborn genetic testing. In short, Bionano Genomics offers tools that can lead to better health outcomes through more accurate diagnoses, improved treatments, and accessible genetic information.
The bigger question is, how can it fail? The technology is here to stay.

Revvity Inc (RVTY): You have an SOS text from BNGO

The stock price has decreased by -85.16% in the last 52 weeks.

BNGO has 101.99 million shares outstanding. The number of shares has increased by 94.65% in one year. DILUTION!!!

In the last 12 months, BNGO had revenue of $33.33 million and -$135.78 million in losses. Loss per share was -$2.21.

The last stock split was on August 7, 2023. It was a reverse split with a ratio of 10 for 1, and in 2025, the reverse split will be 60 for 1.

BNGO has a “Piotroski” F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

The latest short interest is 17.65 million, so 17.31% of the outstanding shares have been sold short.

BNGO has a market cap or net worth of $18.92 million. The enterprise value is $29.42 million.

BNGO has an “ALTMAN” Z-Score of -13.29.
(The Altman Z-Score is a formula used to predict the likelihood of a business going bankrupt within the next two years. A score below 1.8 generally suggests a high probability of bankruptcy, and a score as low as -13.29 is extremely alarming.)

BNGO has a “PIOTROSKI” F Score of 2.
(The Piotroski F-Score is a tool used to evaluate a company's financial strength based on nine criteria, with a score ranging from 0 to 92. A score of 2 means that the company only meets two of these criteria, suggesting significant financial distress and a higher risk of bankruptcy.)

Revvity has a market cap or net worth of $14.94 billion as of January 23, 2025. Its market cap has increased by 12.41% in one year.

BNGO...........................https://stockcharts.com/h-sc/ui?s=BNGO&p=W&b=5&g=0&id=p86431144783

Will China Pressure FDA’s Approval of OGM

China's National Medical Products Administration (NMPA) has approved Bionano Genomics' optical genome mapping (OGM) testing for use in hospitals. This approval allows Bionano's DNA extraction and labeling kits to be used for in vitro diagnostics (IVD) in reproductive health.

The collaboration between the two companies, which combines Bionano's OGM technology with Diagens' AI-based chromosome karyotype analysis, has been instrumental in advancing the adoption of OGM in China's healthcare system.

Diagens believes that combining Bionano's optical genome mapping (OGM) technology with their AI chromosome karyotype analysis can significantly improve the success rate of in vitro fertilization (IVF) and potentially expand into other fields like blood cancer in the future.

International approvals can positively influence the FDA's decision-making process.

Happy New OGM Code 2025!

Category I CPT Code for Bionano Genomics. The code, which went into effect on January 1, 2025, is for the use of optical genome mapping (OGM) in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies.

This approval is significant as it implies acceptance by the medical community and is expected to help with reimbursement for the OGM-Dx™ HemeOne laboratory developed test (LDT) from third-party payers (insurance companies).

The HemeOne laboratory developed test (LDT) is a special test created by Bionano Laboratories to help diagnose and manage blood cancers (hematological malignancies) like leukemia and lymphoma.

The test uses a technique called optical genome mapping (OGM) to look for changes in the DNA that might indicate the presence of these cancers. The test can detect structural variants (SVs) in the DNA that are important for understanding the specific type and characteristics of the lymphoma.

By identifying specific genetic changes, oncologists can tailor treatment plans to target those changes more effectively. This can lead to better outcomes and more personalized care. The test can be used to monitor the patient's response to treatment and detect any potential relapses or changes in the disease over time.

The partnership between Revvity and Bionano Genomics strengthens their position in the genomic testing market, especially for applications requiring detailed genomic analysis. Revvity's substantial resources and expertise in sequencing, paired with Bionano's innovative Stratys system for optical genome mapping (OGM), create a powerful synergy.